Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Conferences

Conference Coverage

Conference Listing

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Articles

If validated prospectively, the classifier could provide oncologists with clearer prognostic insight, enabling more personalized chemotherapy decisions, earlier intervention for high-risk patients, and potential adaptation across STS and other cancer types.

New 9-Gene Classifier May More Accurately Predict Metastasis Across STS, Other Cancers

A chemotherapy-free, MRD-guided regimen achieved deep, durable remissions in untreated MCL with manageable toxicity and the potential for time-limited therapy.

MRD-Guided Therapy Shows Promise as a Time-Limited Frontline Strategy for MCL

A small set of pre-apheresis biological factors can reliably predict whether patients with DLBCL will achieve the T cell collection efficiency needed for successful CAR T manufacturing

Study Identifies Key Predictors of Successful CD3+ Cell Apheresis for CAR T Manufacturing in DLBCL

®). She joined the AJMC team in 2021, where she produces written and video content covering multiple disease states.

She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on 

A review of 560 FDA-approved drugs found the FDAAA did not change overall time to first postmarket safety action, but some actions occurred earlier.

Postmarket Drug Safety Timelines Largely Unchanged After FDA Amendments Act

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

1.125rem

Ira Zackon, MD, is a senior medical director at Ontada. 

Ira Zackon, MD, discusses bispecific antibody use in multiple myeloma among community practices, reflecting real-world treatment trends.

Bispecific Antibodies for Multiple Myeloma in Community Oncology Are on the Rise: Ira Zackon, MD